Vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.
|23/12/2011||04/01/2012||Full Pharmacoeconomic Evaluation Recommended|
|May 2012||03/09/2012||Reimbursement not recommended at the submitted price|
The NCPE believe that, at the submitted price, vemurafenib (Zelboraf®) is not cost effective for this indication
The HSE has approved reimbursement following confidential price negotiations.